 CAMBRIDGE, Mass., April 13, 2021 Synlogic, Inc. Nasdaq: SYBX, a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data from the Phase 1 study of SYNB1618 for the treatment of Phenylketonuria PKU during the American College of Medical Genetics ACMG annual meeting, being held virtually April 13-16, 2021. 